Citations

Mayo Clinic

Clear

6665 citation(s) found for "Xu, William".

The Outcome of Combined-Modality Therapy for Stage III Non–Small-Cell Lung Cancer in the Elderly
Schild, Steven E. , Stella, Philip J., Geyer, Susan M. , Bonner, James A. , McGinnis, William L., Mailliard, James A., Brindle, J., Jatoi, Aminah , Jett, James R., Schild, Steven

Journal of Clinical Oncology | July 22, 2003 | Volume: 21 | Issue: 17 | Pages: 3201-3206

10.1200/jco.2003.12.019 | PMID 12874270 Get It

Purpose: The North Central Cancer Treatment Group performed a phase III trial to determine whether chemotherapy plus either bid radiation therapy (RT) or daily (qd) RT resulted in a better outcome for patients with stage III non–small-cell lung cancer (NSCLC). No difference in survival was identified between the two arms. This secondary analysis was performed to examine the relationship between patient age and outcome. Patients and Methods: Two hundred forty-six patients were randomized to receive etoposide plus cisplatin and either RT qd or split-course RT bid. This retrospective study compared the outcomes of patients aged ≥70 years (“elderly patients”) with those of younger individuals. Of the 244 assessable patients, 63 (26%) were elderly, and 181 (74%) were younger individuals. Results: The 2-year and 5-year survival rates were 39% and 18%, respectively, in patients younger than 70 years, compared with 36% and 13%, respectively, in elderly patients (P = .4). Grade 4+ toxicity occurred in 62% of patients younger than 70 years compared with 81% of elderly patients (P = .007). Grade 4+ hematologic toxicity occurred in 56% of patients younger than 70 years, compared with 78% of elderly patients (P = .003). Grade 4+ pneumonitis occurred in 1% of those younger than 70 years, compared with 6% of elderly patients (P = .02). Conclusion: Toxicity, especially myelosuppression and pneumonitis, was more pronounced in the elderly patients receiving combined-modality therapy for locally advanced NSCLC. Despite increased toxicity, elderly patients have survival rates equivalent to younger individuals. Therefore, fit, elderly patients with locally advanced NSCLC should be encouraged to receive combined-modality therapy, preferably on clinical trials with cautious, judicious monitoring. Future studies should explore ways to decrease toxicity of therapy in elderly patients.
Caveolin-1 Can Regulate Vascular Smooth Muscle Cell Fate by Switching Platelet-Derived Growth Factor Signaling From a Proliferative to an Apoptotic Pathway
Peterson, Timothy E., Guicciardi, Maria Eugenia , Gulati, Rajiv , Kleppe, Laurel S., Mueske, Cheryl S., Mookadam, Martina , Sowa, Grzegorz , Sessa, William C. , Simari, Robert D., Gores, Gregory J.

Arteriosclerosis, Thrombosis, and Vascular Biology | June 24, 2003 | Volume: 23 | Issue: 9 | Pages: 1521-1527

10.1161/01.atv.0000081743.35125.05 | PMID 12816877 Get It

Background— Caveolin-1 is a regulator of signaling events originating from plasma membrane microdomains termed caveolae. This study was performed to determine the regulatory role of caveolin-1 on the proliferative events induced by platelet-derived growth factor (PDGF) in vascular smooth muscle cells (VSMCs). Methods and Results— Treatment of VSMCs with PDGF for 24 hours resulted in a loss of caveolin-1 protein expression and plasma membrane–associated caveolae, despite a 3-fold increase in caveolin-1 mRNA. Pretreatment of VSMCs with chloroquine, an inhibitor of lysosomal function, inhibited the PDGF-induced loss of caveolin-1. These studies demonstrated that caveolin-1 was a target of PDGF signaling events. Adenoviral overexpression of caveolin-1 was associated with a switch in PDGF-induced signaling events from a proliferative response to an apoptotic response. This overexpression inhibited PDGF-induced expression of cyclin D1 in the presence of unaffected mitogen-activated protein kinase activation. Conclusions— Taken together, these studies suggest that caveolin-1 is an inhibitor of PDGF proliferative responses and might be capable of transforming PDGF-induced proliferative signals into death signals.
Cardiovascular Endocrinology: Introduction
Baxter, John D. , Webb, Paul , Young, William F.

Endocrine Reviews | June 4, 2003 | Volume: 24 | Issue: 3 | Pages: 253-260

10.1210/er.2003-0099 | PMID 12788796 Get It

Oxidized Low-Density Lipoprotein Activates Migration and Degranulation of Human Granulocytes
Sedgwick, Julie B., Hwang, Young Sil, Gerbyshak, Heather A., Kita, Hirohito , Busse, William W. , Kita, H

American Journal of Respiratory Cell and Molecular Biology | June 3, 2003 | Volume: 29 | Issue: 6 | Pages: 702-709

10.1165/rcmb.2002-0257oc | PMID 12777245 Get It

Abstract Oxidized low-density lipoprotein (oxLDL) has been reported as a major participant in the pathogenesis of atherosclerosis. We hypothesized that oxLDL can also interact with granulocytes during inflammatory airway diseases, such as asthma. To test the chemotactic effect of oxLDL, isolated human peripheral granulocytes were added to the upper chambers of Transwell filters and migration in response to oxLDL was determined. Cu+2-oxidized LDL stimulated neutrophil (23.4 ± 3.2% for 100 μg/ml oxLDL versus 2.9 ± 1.1% for buffer, P < 0.05) and eosinophil (19.3 ± 3.5% versus 0.6 ± 0.02% for buffer, P < 0.05) chemotaxis in a concentration-dependent manner. The magnitude of chemotaxis was dependent on the degree of LDL oxidation. Granulocyte transmigration across IL-1β–activated human pulmonary microvascular endothelial cell monolayers was similarly stimulated by oxLDL. OxLDL activated significant degranulation of both neutrophils (100.9 ± 9.8 versus 49.6 ± 8.4 ng lactoferrin released/5 × 105 neutrophils for buffer, P < 0.05) and eosinophils (342 ± 115.4 versus 85.8 ± 30.4 ng eosinophil-derived neurotoxin/1 × 106 eosinophils for buffer, P < 0.05). Therefore, in vivo influx and oxidation of LDL may be an important mediator for the initiation of bronchial inflammation where granulocytes are recruited to the lung.
Prognostic Implications of Physiologic and Radiographic Changes in Idiopathic Interstitial Pneumonia
Flaherty, Kevin R. , Mumford, Jeanette A. , Murray, Susan , Kazerooni, Ella A. , Gross, Barry H., Colby, Thomas V. , Flint, Andrew , Toews, Galen B., Lynch, Joseph P., Travis, William D. , Martínez, Fernando J.

American Journal of Respiratory and Critical Care Medicine | June 3, 2003 | Volume: 168 | Issue: 5 | Pages: 543-548

10.1164/rccm.200209-1112oc | PMID 12773329 Get It

Abstract Idiopathic interstitial pneumonias are a diverse group of lung diseases with varied prognoses. We hypothesized that changes in physiologic and radiographic parameters would predict survival. We retrospectively examined 80 patients with usual interstitial pneumonia and 29 patients with nonspecific interstitial pneumonia. Baseline characteristics were examined together with 6-month change in forced vital capacity, diffusing capacity for carbon monoxide, and ground glass infiltrate and fibrosis on high resolution computed tomography. Patients with usual interstitial pneumonia were more likely to have a statistically significant or marginally significant decline in lung volume, diffusing capacity for carbon monoxide, and an increase in ground glass infiltrates (p ⩽ 0.08) compared with patients with nonspecific interstitial pneumonia. For patients with usual interstitial pneumonia, change in forced vital capacity was the best physiologic predictor of mortality (p = 0.05). In a multivariate Cox proportional hazards model controlling for histopathologic diagnosis, gender, smoking history, baseline forced vital capacity, and 6-month change in forced vital capacity, a decrease in forced vital capacity remained an independent risk factor for mortality (decrease > 10%; hazard ratio 2.47; 95% confidence interval 1.29, 4.73; p = 0.006). We conclude that a 6-month change in forced vital capacity gives additional prognostic information to baseline features for patients with idiopathic interstitial pneumonia.
Additional Radiation Absorbed Dose Estimates for Zevalin™ Radioimmunotherapy
Wiseman, Gregory A., Leigh, Bryan R., Dunn, William L., Stabin, Michael G. , White, Christine A.

Cancer Biotherapy and Radiopharmaceuticals | May 21, 2003 | Volume: 18 | Issue: 2 | Pages: 253-258

10.1089/108497803765036436 | PMID 12804052 Get It

Radiation Dosimetry Results From a Phase II Trial of Ibritumomab Tiuxetan (Zevalin™) Radioimmunotherapy for Patients With Non-Hodgkin's Lymphoma and Mild Thrombocytopenia
Wiseman, Gregory A., Leigh, Bryan R., Erwin, William D. , Sparks, Richard, Podoloff, Donald A., Schilder, Russell J., Spies, Stewart, Grillo-López, Antonio J, White, Christine A., Bartlett, Nancy L. , Witzig, Thomas E.

Cancer Biotherapy and Radiopharmaceuticals | May 21, 2003 | Volume: 18 | Issue: 2 | Pages: 165-178

10.1089/108497803765036337 | PMID 12804042 Get It

Minireview: Primary Aldosteronism—Changing Concepts in Diagnosis and Treatment
Young, William F.

Endocrinology | May 14, 2003 | Volume: 144 | Issue: 6 | Pages: 2208-2213

10.1210/en.2003-0279 | PMID 12746276 Get It

AbstractPrimary aldosteronism affects 5–13% of patients with hypertension. Patients with hypertension and hypokalemia and most patients with treatment-resistant hypertension should undergo screening for primary aldosteronism with a plasma aldosterone concentration to plasma renin activity ratio. A high plasma aldosterone concentration to plasma renin activity ratio is a positive screening test result, a finding that warrants confirmatory testing. For those patients that want to pursue a surgical cure, the accurate distinction between the subtypes (unilateral vs. bilateral adrenal disease) of primary aldosteronism is a critical step. The subtype evaluation may require one or more tests, the first of which is imaging the adrenal glands with computed tomography, followed by selective use of adrenal venous sampling. Because of the deleterious cardiovascular effects of aldosterone, normalization of circulating aldosterone or aldosterone receptor blockade should be part of the management plan for all patients with primary aldosteronism. Unilateral laparoscopic adrenalectomy is an excellent treatment option for patients with unilateral aldosterone-producing adenoma. Bilateral idiopathic hyperaldosteronism should be treated medically. In addition, aldosterone-producing adenoma patients may be treated medically if the medical treatment includes mineralocorticoid receptor blockade.
Fibroblastic Foci in Usual Interstitial Pneumonia: Idiopathic versus Collagen Vascular Disease
Flaherty, Kevin R. , Colby, Thomas V. , Toews, Galen B., Mumford, Jeanette A. , Murray, Susan , Kazerooni, Ella A. , Gross, Barry H., Lynch, Joseph P., Travis, William D. , Thannickal, Victor J. , Martínez, Fernando J.

American Journal of Respiratory and Critical Care Medicine | May 8, 2003 | Volume: 167 | Issue: 10 | Pages: 1410-1415

10.1164/rccm.200204-373oc | PMID 12615630 Get It

Abstract A histologic feature of usual interstitial pneumonia is the presence of fibroblastic foci. As some patients with usual interstitial pneumonia and an underlying collagen vascular disease have a better prognosis, we hypothesized that they would have fewer fibroblastic foci. Pathologists reviewed surgical lung biopsies from 108 patients with usual interstitial pneumonia (nine with collagen vascular disease) and assigned a score (absent 0, mild 1, moderate 2, and marked 3) for fibroblastic foci. Patients with idiopathic usual interstitial pneumonia had a higher median profusion of fibroblastic foci (1.75 vs. 1.0, p = 0.003). Baseline characteristics were similar, although patients with a collagen vascular disease were younger, had a shorter duration of symptoms, and had a higher percentage of predicted total lung capacity. Profusion of fibroblastic foci was the most discriminative feature for separating idiopathic from collagen vascular disease–associated usual interstitial pneumonia (odds ratio 8.31; 95% confidence interval, 1.98, 59.42; p = 0.002 for a one-unit increase in fibroblastic foci score). No deaths were noted in the collagen vascular disease–associated usual interstitial pneumonia group; 52 deaths occurred in the idiopathic usual interstitial pneumonia group (log rank; p = 0.005). We conclude that patients with collagen vascular disease–associated usual interstitial pneumonia have fewer fibroblastic foci and improved survival.
Hyperhomocysteinemia accelerates atherosclerosis in cystathionine β-synthase and apolipoprotein E double knock-out mice with and without dietary perturbation
Wang, Hong , Yang, Fan , Gaubatz, John W. , Ma, Lang , Magera, Mark J , Yang, Xiao-Feng, Berger, Peter B. , Pownall, Henry J. , Schafer, Andrew I. , Jiang, Xiaohua , Durante, William , Pownall, Henry J

Blood | May 5, 2003 | Volume: 101 | Issue: 10 | Pages: 3901-3907

10.1182/blood-2002-08-2606 | PMID 12506016 Get It

AbstractAlthough hyperhomocysteinemia is an independent risk factor for cardiovascular disease, a direct role for homocysteine (Hcy) in this disease remains to be shown. Whereas diet-induced hyperhomocysteinemia promotes atherosclerosis in animal models, the effects of Hcy on atherogenesis in the absence of dietary perturbations is not known. We have generated double knock-out mice with targeted deletions of the genes for apolipoprotein E (apoE) and cystathionine β-synthase (CBS), which converts Hcy to cystathionine. ApoE−/−/CBS−/− mice developed aortic lesions even in the absence of dietary manipulation; lesion area and lesion cholesteryl ester (CE) and triglyceride (TG) contents increased with animal age and plasma Hcy levels. Plasma total cholesterol was significantly increased, whereas high density lipoprotein (HDL) cholesterol and TG concentrations of apoE−/−/CBS−/− mice were decreased. Cholesterol esterification and activities of enzymes catalyzing CE or TG formation in the vessel wall and in peritoneal macrophages were not changed by hyperhomocysteinemia. However, uptake of human acetyl-LDL, but not native low density lipoprotein (LDL), by mouse peritoneal macrophages was higher in the presence of hyperhomocysteinemia. These results suggest that isolated hyperhomocysteinemia is atherogenic and alters hepatic and macrophage lipoprotein metabolism, in part, by enhancing uptake of modified LDL.